Related Experiment Video
Updated: Jun 28, 2026

Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells
Published on: January 6, 2014
[Cancer vaccine]
Hisashi Wada1, Yuichiro Doki, Eiichi Nakayama
1Department of Surgery, Osaka University, Graduate School of Medicine.
Abstract:
The existence of anti-tumor immune system has been reported and was proved by many experiments. A lot of tumor specific antigens as a target of immune system were identified and some have been applied for cancer vaccine. Since NY-ESO-1, one of cancer-testis antigens, was reported to be expressed frequently in cancers and to possess strong immunogenicity, it is also used for worldwide cancer vaccine trials. We have performed a cancer vaccine clinical trial with NY-ESO-1 protein and observed NY-ESO -1 specific immune responses in most of patients vaccinated. Some patients showed preferable clinical responses. Cancer vaccine was developed rapidly in the last decade, however there still left several problems to be resolved for the spread of cancer vaccine.
Insights
Cancer vaccines targeting NY-ESO-1 antigen show promise, with most patients developing immune responses. Further research is needed to overcome challenges for widespread cancer vaccine adoption.
Area of Science:
- Immunology
- Oncology
- Vaccinology
Context:
- The anti-tumor immune system's existence is well-established, with numerous tumor-specific antigens identified for cancer vaccine development.
- Cancer-testis antigens, like NY-ESO-1, are frequently expressed in various cancers and exhibit strong immunogenicity, making them attractive vaccine targets.
Purpose:
- To evaluate the efficacy of a cancer vaccine utilizing NY-ESO-1 protein in eliciting anti-tumor immune responses.
- To assess clinical responses in patients vaccinated with NY-ESO-1 protein.
Summary:
- A clinical trial involving an NY-ESO-1 protein cancer vaccine demonstrated significant NY-ESO-1 specific immune responses in the majority of vaccinated patients.
- A subset of patients experienced favorable clinical outcomes following vaccination.
Impact:
- This study contributes to the rapid advancement of cancer vaccine technology.
- Identifies the need to address remaining challenges for the broader clinical application of cancer vaccines.
More Related Videos
09:15Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
Published on: February 24, 2023
10:18Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction
Published on: July 7, 2023
Related Concept Videos
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer Prevention
Some...
Cancer Prevention
Some...
Cancer
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...